Compared to Estimates, Dentsply (XRAY) Q3 Earnings: A Look at Key Metrics

Dentsply International (XRAY) reported $904 million in revenue for the quarter ended September 2025, representing a year-over-year decline of 4.9%. EPS of $0.37 for the same period compares to $0.50 a year ago.The reported revenue represents a surprise of +0.27% over the Zacks Consensus Estimate of $901.59 million. With the consensus EPS estimate being $0.45, the EPS surprise was -17.78%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Dentsply performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Revenues- United States: $291 million versus $333.9 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -22.2% change.Revenues- Rest of World: $231 million versus $211.1 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +0.4% change.Revenues- Europe: $382 million versus the three-analyst average estimate of $360.92 million. The reported number represents a year-over-year change of +10.1%.Net sales- Connected Technology Solutions: $259 million compared to the $253.17 million average estimate based on five analysts. The reported number represents a change of -3.7% year over year.Net sales- Wellspect Healthcare: $83 million versus $76.63 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +15.3% change.Net sales- Essential Dental Solutions: $357 million versus the five-analyst average estimate of $367.93 million. The reported number represents a year-over-year change of -3.3%.Net sales- Orthodontic and Implant Solutions: $205 million versus $202.59 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -14.9% change.Adjusted Operating Income- Connected Technology Solutions: $10 million versus $19.2 million estimated by two analysts on average.Adjusted Operating Income- Wellspect Healthcare: $28 million compared to the $24 million average estimate based on two analysts.Adjusted Operating Income- Orthodontic and Implant Solutions: $22 million versus $15.66 million estimated by two analysts on average.Adjusted Operating Income- Essential Dental Solutions: $116 million versus $127.61 million estimated by two analysts on average.View all Key Company Metrics for Dentsply here>>>Shares of Dentsply have returned +1.9% over the past month versus the Zacks S&P 500 composite's +1.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DENTSPLY SIRONA Inc. (XRAY): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks